The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,264.00
Bid: 12,264.00
Ask: 12,266.00
Change: -140.00 (-1.13%)
Spread: 2.00 (0.016%)
Open: 12,334.00
High: 12,362.00
Low: 12,250.00
Prev. Close: 12,404.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Germany struggles to shift AstraZeneca vaccine doses

Thu, 25th Mar 2021 16:19

* Germany has administered just 60% of delivered AZ
doses-RKI data

* Merkel says "not ok" if vaccination appointments going
unused

* Scepticism, patchy state rollout, data monitoring play a
role

By Caroline Copley

BERLIN, March 25 (Reuters) - Berlin pensioner Gerhard
Schaeufele decided he'd prefer to wait 10 days and cross the
city for a shot of the BioNTech/Pfizer
coronavirus vaccine, rather than accept an AstraZeneca vaccine
in two days' time at his local centre.

"A week ago, maybe I would have taken AstraZeneca," the
72-year-old retired university arts teacher told Reuters,
describing himself as someone who follows his gut feeling.

But he said the recent back-and-forth over the vaccine's
efficacy and safety put him off.

AstraZeneca says its vaccine is safe and effective, citing
extensive trial data. Millions of doses have been safely
administered around the world and the EU's medicines watchdog
and the World Health Organisation have reaffirmed it safe. Most
of the states which briefly halted its use, including Germany,
have resumed giving the shot.

However, Schaeufele's hesitancy towards AstraZeneca's shot
underscores the challenge Berlin faces as it seeks to ramp up
its sluggish vaccine rollout while contending with a third wave
of the pandemic, driven by more infectious virus variants.

It's an issue faced by governments across the European Union
as they seek to get their vaccine rollouts back on track. A
third of Danes say they won't accept the Anglo-Swedish shot,
while some in France remain sceptical.

According to data from the Robert Koch Institute (RKI) of
infectious diseases, around 2.1 million or 60 percent of the
doses of AstraZeneca's vaccine to arrive in Germany have been
used. By comparison 83% of BioNTech/Pfizer vaccines have been
used.

A survey of Germany's states, who are responsible for the
vaccine rollout, suggests the low take-up is attributable in
part to organisational bottlenecks as well as people's
uncertainty over the AstraZeneca vaccine.

Chancellor Angela Merkel, 66, who is facing growing
criticism over her handling of the pandemic, has said she would
herself accept the AstraZeneca vaccine when her turn came.

She told the Bundestag on Thursday that it was "not ok" that
appointments were going unused.

In Berlin, the AstraZeneca shot is available at former
airports Tegel and Tempelhof, and appointments were available to
those eligible as soon as this coming weekend when Reuters
checked on Thursday.

At Berlin's four other centres, which administer BioNTech
and Moderna, no time slots were available within the
next month.

BUREAUCRATIC BACKLOGS

In Bremen, the country's smallest state, 80% of its
AstraZeneca doses have been administered with local officials
saying they were quick to offer appointments to teachers and
daycare staff once the priority list was amended on Feb. 24.

In Saxony by contrast, less than 30% of its AstraZeneca
doses have so far been used. The state has not yet made the
vaccine available in hospitals although medical staff would be
eligible, according to a person working on the rollout.

A spokeswoman for the health ministry in the state of
Saxony-Anhalt said the initial recommendation that the
AstraZeneca shot only be given to those under 65 had acted as a
hindrance, citing "greater organisational effort" to arrange
appointments for those in the next priority group.

Meanwhile, in Mecklenburg-Vorpommern, shots were delayed
after 12,200 AZ doses had to be put in "quarantine" for a week
due to an error in the cold chain of the delivery company.

One of the biggest hurdles for the rollout has been
inconsistent deliveries and supply constraints. But this is set
to change with deliveries of around 15 million doses in total of
all three approved vaccines in April.

Ruth Waldmann, health spokesperson for the Social Democrats
in the Bavarian state parliament, said it was time to "fire up
the vaccination turbo" by bringing on board family doctors.

Germany plans to supply doctors with a million vaccines per
week from April rising to three million by the end of the month,
and hopes this will add more firepower and flexibility to its
rollout.

Family doctors could easily inoculate 2.5 million people per
week if each practice does just 10 shots per day, according to
the national association.
(Reporting by Caroline Copley
Additional reporting by Michael Nienaber, Thomas Escritt and
Christina Amann
Editing by Alexandra Hudson)

More News
22 May 2024 09:53

LONDON BROKER RATINGS: Barclays cuts NextEnergy but lifts JLEN

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday:

Read more
22 May 2024 02:00

British firms expecting hard time in China market, lobby group warns

BEIJING, May 22 (Reuters) - British firms expect doing business in China to become harder over the next five years, a British business lobby group said on Wednesday, as Beijing strives to halt a retreat in foreign funds from a market once seen as the engine of global growth.

Read more
21 May 2024 19:00

Sector movers: Stocks slip amid light profit-taking

(Sharecast News) - Stocks ended a tad lower as investors waited on a raft of US central bank speakers scheduled for after the close of markets in London.

Read more
21 May 2024 17:20

Europe's STOXX 600 ends lower as rate uncertainty prevails

Focus on Fed minutes, Nvidia earnings

*

Read more
21 May 2024 17:04

LONDON MARKET CLOSE: London dips as eyes turn to UK inflation reading

(Alliance News) - Stock prices in London closed in the red on Tuesday, as investors nervously eye a key UK inflation reading, which could prompt the Bank of England to consider interest rate cuts.

Read more
21 May 2024 15:00

London close: Stocks fall ahead of key inflation reading

(Sharecast News) - London stocks ended in negative territory on Tuesday, influenced by the latest UK economic outlook from the International Monetary Fund (IMF) and comments from US Federal Reserve officials.

Read more
21 May 2024 12:03

CORRECT: Stocks fall but pound up as IMF ups UK forecast

(Correcting London Stock Exchange index prices.)

Read more
21 May 2024 12:00

LONDON MARKET MIDDAY: Stocks fall but pound up as IMF ups UK forecast

(Alliance News) - Stock prices in Europe were lower heading into Tuesday afternoon, with shares in New York also set for a muted open, as a recent rally for equities takes a pause.

Read more
21 May 2024 11:23

AstraZeneca aims for $80 bln in total revenue by 2030

Sees $80 bln in 2030 revenue by 2030

*

Read more
21 May 2024 09:04

LONDON MARKET OPEN: FTSE 100 declines after Asian stocks fall

(Alliance News) - Stock prices in London opened in the red on Tuesday, with some US interest rate cut optimism cooling after hawkish words from Federal Reserve central bankers.

Read more
21 May 2024 08:18

TOP NEWS: AstraZeneca eyes new era of growth with bold new revenue aim

(Alliance News) - AstraZeneca PLC on Tuesday set out its ambition to achieve USD80 billion in annual revenue by the end of the decade as it signalled a new "era of growth."

Read more
21 May 2024 07:52

LONDON BRIEFING: AstraZeneca plots "new era of growth"; SSP confident

(Alliance News) - London's FTSE 100 is called to open lower on Tuesday, following a mixed close in New York overnight, and tepid trade in Asia.

Read more
21 May 2024 07:34

AstraZeneca lays out plans to hit $80bn in revenues by 2030

(Sharecast News) - AstraZeneca has unveiled medium-term growth targets to nearly double group revenues by the end of the decade as it predicts significant growth from existing oncology, biopharmaceuticals and rare disease portfolios.

Read more
20 May 2024 11:55

LONDON MARKET MIDDAY: Gold shines amid interest rate cut hopes

(Alliance News) - Stock prices in London got a boost at midday on Monday, as investors eye a key UK inflation reading later in the week, which is expected to show cooling prices.

Read more
20 May 2024 08:56

AstraZeneca to build $1.5-bln cancer drug plant in Singapore

Plans to build ADCs manufacturing facility in Singapore

*

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.